Overview of the 2022 WHO classification of thyroid neoplasms
This review summarizes the changes in the 5th edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new …
Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new …
[HTML][HTML] Novel therapeutics in radioactive iodine-resistant thyroid cancer
T Fullmer, ME Cabanillas, M Zafereo - Frontiers in Endocrinology, 2021 - frontiersin.org
Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until
recently, there were limited therapeutic options. However, over the last decade our …
recently, there were limited therapeutic options. However, over the last decade our …
[HTML][HTML] RBM47/SNHG5/FOXO3 axis activates autophagy and inhibits cell proliferation in papillary thyroid carcinoma
Y Qin, W Sun, Z Wang, W Dong, L He, T Zhang… - Cell death & …, 2022 - nature.com
Papillary thyroid carcinoma (PTC) is the main type of thyroid carcinoma. Despite the good
prognosis, some PTC patients may deteriorate into more aggressive diseases, leading to …
prognosis, some PTC patients may deteriorate into more aggressive diseases, leading to …
[HTML][HTML] Novel inhibitor-based therapies for thyroid cancer—An update
M Ratajczak, D Gaweł, M Godlewska - International journal of molecular …, 2021 - mdpi.com
Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …
rise in the number of TC cases has been observed for the past few decades. TCs are one of …
[HTML][HTML] Dynamic cancer cell heterogeneity: Diagnostic and therapeutic implications
V Jacquemin, M Antoine, G Dom, V Detours… - Cancers, 2022 - mdpi.com
Simple Summary Cancer heterogeneity, which occurs in most cancer patients, has been
known and studied by experienced pathologists since the early 19th century. Intratumoral …
known and studied by experienced pathologists since the early 19th century. Intratumoral …
[HTML][HTML] Poorly differentiated thyroid carcinoma: a clinician's perspective
J Tong, M Ruan, Y Jin, H Fu, L Cheng… - European Thyroid …, 2022 - etj.bioscientifica.com
Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …
[HTML][HTML] Update on current diagnosis and management of anaplastic thyroid carcinoma
ET Pavlidis, IN Galanis, TE Pavlidis - World Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Well-differentiated thyroid carcinoma has a favorable prognosis with a 5-year survival rate of
over 95%. However, the undifferentiated or anaplastic type accounting for< 0.2%, usually in …
over 95%. However, the undifferentiated or anaplastic type accounting for< 0.2%, usually in …
NEAT1_2/RRAD/EHF positive feedback loop facilitates aerobic glycolysis in papillary thyroid cancer cells
W Sun, Z Wang, Y Qin, X Ji, J Huang, F Zhang… - …, 2023 - academic.oup.com
Papillary thyroid carcinoma (PTC) is the most prevalent endocrine-related malignancy. In
spite of the good prognosis, a more aggressive disease can develop in some PTC patients …
spite of the good prognosis, a more aggressive disease can develop in some PTC patients …
[HTML][HTML] Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid Production
DB Allison, J Rueckert, V Cornea, CY Lee, J Dueber… - Endocrine …, 2022 - Springer
In this report, we present a high-grade thyroid carcinoma with an NSD3:: NUTM1 fusion
detected on expanded next-generation sequencing testing. Nuclear protein of the testis …
detected on expanded next-generation sequencing testing. Nuclear protein of the testis …
Thyroid cancer under the scope of emerging technologies
M Tarabichi, P Demetter, L Craciun, C Maenhaut… - Molecular and cellular …, 2022 - Elsevier
The vast majority of thyroid cancers originate from follicular cells. We outline outstanding
issues at each step along the path of cancer patient care, from prevention to post-treatment …
issues at each step along the path of cancer patient care, from prevention to post-treatment …